Skip to content

US · SXTP · BIOTECHNOLOGY

60 Degrees Pharmaceuticals, Inc. (SXTP) intrinsic value and stock valuation

$0.47as of 2026-11-21 · Mkt cap 983.99K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

60 Degrees Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values SXTP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SXTP’s statements →

60 Degrees Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Washington, DC 20036 60degreespharma.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$1.01M-14.3% 5y CAGRd
20202025
Net income
-$-7.37M
20202025
Free cash flow
-$-7.07M
20202025
Total equity
$3.38M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$1.01M$610K$250K$220K$1.16M
Operating income-$-7.76M-$-9.71M-$-5.15M-$-1.75M-$-1.12M
Net income-$-7.37M-$-7.95M-$-3.77M-$-6.18M-$-4.25M
EPSd-$-11M-$-72.27M-$-188.5M-$-309M-$-212.5M
Operating cash flow-$-6.85M-$-5.65M-$-4.54M-$-1.01M-$-650K
Capital expenditure-$-220K-$-180K-$-120K-$-60K-$-40K
Free cash flow-$-7.07M-$-5.83M-$-4.66M-$-1.07M-$-680K
Total assets$5.37M$5.76M$7.78M$1.3M$1.39M
Total debt$150K$160K$170K$22.4M$18.8M
Net debt-$-1.36M-$-1.5M-$-1.97M$22.2M$18.7M
Total equity$3.38M$3.96M$4.8M-$-24.15M-$-18.15M
Cash and short-term investments$2.75M$3.39M$2.14M$260K$120K
Income statement
20252024202320222021
Revenue$1.01M$610K$250K$220K$1.16M
Cost of revenue$780K$380K$470K$430K$850K
Gross profit$220K$220K-$-220K-$-210K$310K
Research and development expenses$2.11M$4.99M$690K$530K$5.51M
Selling, general and administrative expenses$6.28M$5.02M$4.24M$1.3M$1.12M
Other expenses-$-400K-$-70K$0.00-$-290K-$-5.19M
Operating expenses$7.98M$9.94M$4.93M$1.54M$1.43M
Cost and expenses$8.76M$10.3M$5.41M$1.97M$2.28M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$10K$10K$2.29M$3.99M$3.17M
Depreciation and amortization$80K$60K$100K$80K$70K
Ebitda-$-7.28M-$-7.88M-$-1.43M-$-2.11M-$-1.01M
Operating income-$-7.76M-$-9.71M-$-5.15M-$-1.75M-$-1.12M
Total other income/expenses, net$390K$1.76M$1.34M-$-4.43M-$-3.14M
Income before tax-$-7.37M-$-7.96M-$-3.81M-$-6.18M-$-4.26M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.37M-$-7.95M-$-3.77M-$-6.18M-$-4.25M
Weighted average shares outstanding$670K$110K$20K$20K$20K
Weighted average diluted shares outstanding$670K$110K$20K$20K$20K
Balance sheet
20252024202320222021
Cash and short-term investments$2.75M$3.39M$2.14M$260K$120K
Net receivables$510K$490K$230K$50K$150K
Inventory$660K$440K$470K$520K$690K
Total current assets$4.9M$5.39M$7.24M$1.1M$1.18M
Property, plant and equipment, net$250K$150K$70K$30K$110K
Goodwill and intangible assets$220K$160K$230K$160K$110K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$470K$370K$540K$200K$220K
Total assets$5.37M$5.76M$7.78M$1.3M$1.39M
Accounts payable$1.46M$1.01M$510K$760K$590K
Short-term debt$10K$10K$20K$21.2M$140K
Deferred revenue$0.00$0.00$0.00$330K$0.00
Total current liabilities$1.84M$1.66M$2.84M$23.9M$640K
Long-term debt$140K$150K$150K$1.27M$18.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$140K$150K$150K$1.53M$18.9M
Capital lease obligations$0.00$0.00$10K$10K$60K
Total liabilities$1.99M$1.8M$2.99M$25.5M$19.6M
Common stock$0.00$0.00$0.00$0.00$4.98M
Retained earnings-$-47.89M-$-40.53M-$-32.58M-$-28.82M-$-22.63M
Accumulated other comprehensive income (loss)$140K$140K$140K$70K$80K
Total equity$3.38M$3.96M$4.8M-$-24.15M-$-18.15M
Total investments$1.24M$1.73M$0.00$0.00$0.00
Total debt$150K$160K$170K$22.4M$18.8M
Net debt-$-1.36M-$-1.5M-$-1.97M$22.2M$18.7M
Cash flow statement
20252024202320222021
Net income-$-7.37M-$-7.96M-$-3.77M-$-6.18M-$-4.26M
Depreciation and amortization$80K$60K$100K$80K$70K
Stock-based compensation$460K$3.61M$0.00$0.00$0.00
Change in working capital-$-10K$190K$410K$3.31M$2.9M
Accounts receivable-$-20K-$-260K-$-190K$100K$710K
Inventory-$-470K$20K$210K-$-50K$310K
Accounts payable$490K$500K-$-210K$170K-$-840K
Net cash provided by operating activities-$-6.85M-$-5.65M-$-4.54M-$-1.01M-$-650K
Investments in property, plant and equipment-$-220K-$-100K-$-60K-$-60K-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$250K-$-1.89M-$-120K-$-60K-$-40K
Common stock issued$6.46M$7.04M$6.45M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.44M$7.05M$6.47M$1.22M$610K
Net change in cash-$-150K-$-480K$1.88M$150K-$-80K
Cash at end of period$1.51M$1.66M$2.14M$260K$120K
Operating cash flow-$-6.85M-$-5.65M-$-4.54M-$-1.01M-$-650K
Capital expenditure-$-220K-$-180K-$-120K-$-60K-$-40K
Free cash flow-$-7.07M-$-5.83M-$-4.66M-$-1.07M-$-680K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 60 Degrees Pharmaceuticals, Inc.

        60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

        CEO
        Geoffrey Stuart Dow
        Employees
        3
        Beta
        2.48

        Explore

        Frequently asked questions

        What is the intrinsic value of 60 Degrees Pharmaceuticals, Inc. (SXTP)?

        InvestorsCraft does not currently publish an intrinsic value for SXTP. How the IC value is calculated.

        Is SXTP undervalued?

        InvestorsCraft does not publish an undervaluation signal for SXTP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.